Literature DB >> 1424166

Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age.

J MacNaughton1, M Banah, P McCloud, J Hee, H Burger.   

Abstract

OBJECTIVE: In women over the age of 45 years with continuing regular menstrual cycles, follicular phase FSH levels rise without an accompanying change in LH. We determined the effect of increasing age in women with regular cycles on the serum levels of FSH, LH, immunoreactive inhibin, progesterone and oestradiol.
DESIGN: Single blood samples were taken during the early follicular phase (days 4-7) and again in the midluteal phase (3-12 days before the next menses) of the menstrual cycle. PATIENTS: Regularly cycling women aged 21-49 years participated in the study (and were grouped into four groups: 20-29, 30-39, 40-44 and 45-49 years in the follicular phase and three groups: 20-29, 30-39 and 40-49 years in the luteal phase. MEASUREMENTS: Serum levels of FSH, LH, oestradiol, progesterone and immunoreactive inhibin were measured from the blood samples obtained.
RESULTS: Follicular phase Mean follicular phase levels of immunoreactive inhibin were significantly lower in the 45-49 year age group (P less than 0.05) than in the younger age groups (128 U/l in the 45-49 year age group vs 239, 235 and 207 U/l in the 20-29, 30-39, 40-44 year age groups respectively), while mean FSH levels were significantly higher in the 45-49 year age group (P less than 0.05, 13.0 IU/l in the 45-49, 4.9, 5.5 and 5.2 IU/l in the 20-29, 30-39 and 40-44 year age groups respectively). Mean oestradiol levels in the 45-49 year age group were significantly lower only when compared to age group 30-39 years (P less than 0.05, 130 vs 210 pmol/l). There was no significant difference in oestradiol levels between the 45-49 year age group and the 20-29 and 40-44 year age groups. LH levels did not differ significantly across age groups. There was also a significant negative correlation between serum immunoreactive inhibin and FSH (r = -0.45, P less than 0.05) and between oestradiol and FSH (r = -0.35, P less than 0.05). There was a significant negative relationship between immunoreactive inhibin and age (r = -0.46, P less than 0.05). For every 10-year increase in age, average immunoreactive inhibin decreased by an estimated 49.3 U/l. As age increased, average FSH levels exhibited a two-phase linear increase with the change-point estimated at 42.97 (1.42) (estimate (SE)) years. Prior to 42.97 years, FSH barely changed; after 42.97 years there was a significant (P less than 0.05) increase in FSH as age increased. Oestradiol levels did not change significantly until an estimated 37.9 years of age, but then decreased significantly (P less than 0.05) with increasing age. Luteal phase Levels of FSH, LH, serum immunoreactive inhibin, oestradiol and progesterone fell slowly with increasing age. There was a significant correlation between serum immunoreactive inhibin with progesterone (r = 0.41, P less than 0.05) but there was no correlation between serum immunoreactive inhibin LH or FSH.
CONCLUSION: The results are consistent with a role for serum immunoreactive inhibin, in addition to oestradiol, in the regulation of FSH during the follicular phase of the menstrual cycle as a function of increasing age. This is postulated to reflect diminished folliculogenesis as age progresses with the known decline in the numbers of primordial follicles in the ovary as the menopause approaches.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424166     DOI: 10.1111/j.1365-2265.1992.tb01457.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  28 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

2.  Trisomic pregnancy and earlier age at menopause.

Authors:  J Kline; A Kinney; B Levin; D Warburton
Journal:  Am J Hum Genet       Date:  2000-06-28       Impact factor: 11.025

Review 3.  Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation.

Authors:  Jerilynn C Prior
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

4.  Predicting pregnancy in women undergoing in-vitro fertilization with basal serum follicle stimulating hormone levels between 10.0 and 11.9 IU/L.

Authors:  Dan Levin; Sunny H Jun; Michael H Dahan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  A characterization of the relationship of ovarian reserve markers with age.

Authors:  Mitchell P Rosen; Erica Johnstone; Charles E McCulloch; Sonya M Schuh-Huerta; Barbara Sternfeld; Renee A Reijo-Pera; Marcelle I Cedars
Journal:  Fertil Steril       Date:  2011-11-30       Impact factor: 7.329

6.  In vitro fertilization outcome according to age and follicle-stimulating hormone levels on cycle day 3.

Authors:  S Bassil; P A Godin; S Gillerot; J C Verougstraete; J Donnez
Journal:  J Assist Reprod Genet       Date:  1999-05       Impact factor: 3.412

7.  A lower antral follicle count is associated with infertility.

Authors:  Mitchell P Rosen; Erica Johnstone; Carolyne Addauan-Andersen; Marcelle I Cedars
Journal:  Fertil Steril       Date:  2011-03-03       Impact factor: 7.329

8.  Compensatory Increase in Ovarian Aromatase in Older Regularly Cycling Women.

Authors:  N D Shaw; S S Srouji; C K Welt; K H Cox; J H Fox; J A Adams; P M Sluss; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  2015-06-30       Impact factor: 5.958

9.  Salivary cortisol and DHEA levels in the Korean population: age-related differences, diurnal rhythm, and correlations with serum levels.

Authors:  Ryun-Sup Ahn; Young-Jin Lee; Jun-Young Choi; Hyuk-Bang Kwon; Sae-Il Chun
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

10.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.